Aigen Investment Management LP Invests $180,000 in Bausch Health Companies Inc. (NYSE:BHC)

Aigen Investment Management LP purchased a new stake in Bausch Health Companies Inc. (NYSE:BHC) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,316 shares of the company’s stock, valued at approximately $180,000.

Several other institutional investors and hedge funds have also bought and sold shares of BHC. Tobam raised its position in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after buying an additional 1,422 shares in the last quarter. DGS Capital Management LLC bought a new position in Bausch Health Companies in the fourth quarter valued at approximately $143,000. Principal Securities Inc. raised its position in Bausch Health Companies by 39.7% during the fourth quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock valued at $155,000 after purchasing an additional 5,464 shares in the last quarter. Merit Financial Group LLC bought a new stake in Bausch Health Companies during the fourth quarter worth $228,000. Finally, Sanders Morris Harris LLC boosted its holdings in shares of Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after purchasing an additional 4,000 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Down 1.0 %

Shares of BHC stock opened at $7.14 on Monday. Bausch Health Companies Inc. has a twelve month low of $3.96 and a twelve month high of $11.46. The stock’s fifty day simple moving average is $7.31 and its 200 day simple moving average is $7.63. The firm has a market capitalization of $2.63 billion, a P/E ratio of -59.45, a P/E/G ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. As a group, equities research analysts expect that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on BHC. Jefferies Financial Group reissued a “hold” rating and set a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada lowered their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.